DCLK1 and renal cell carcinoma: Finally, we note that, despite our use of higher concentrations for some assays, treatment with 1 μM of DCLK1-IN-1 consistently led to reduced expression of N-Cadherin, C-Myc, and C-Met and functional decreases in RCC cell migration, clonogenicity, and stemness.